These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7786634)

  • 21. Inhibition of bone resorption by pamidronate cannot restore normal gain in cortical bone mass and strength in tail-suspended rapidly growing rats.
    Kodama Y; Nakayama K; Fuse H; Fukumoto S; Kawahara H; Takahashi H; Kurokawa T; Sekiguchi C; Nakamura T; Matsumoto T
    J Bone Miner Res; 1997 Jul; 12(7):1058-67. PubMed ID: 9200005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
    Kimoto A; Tanaka M; Nozaki K; Mori M; Fukushima S; Mori H; Shiroya T; Nakamura T
    Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat.
    Schenk R; Eggli P; Fleisch H; Rosini S
    Calcif Tissue Int; 1986 Jun; 38(6):342-9. PubMed ID: 3089557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different schedules of administration of (3 amino-1-hydroxypropylidene)-1, 1 bisphosphonate induce different changes in pig bone remodeling.
    de Vernejoul MC; Pointillart A; Bergot C; Bielakoff J; Morieux C; Laval Jeantet AM; Miravet L
    Calcif Tissue Int; 1987 Mar; 40(3):160-5. PubMed ID: 3105847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment.
    Pataki A; Müller K; Green JR; Ma YF; Li QN; Jee WS
    Anat Rec; 1997 Dec; 249(4):458-68. PubMed ID: 9415453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgens contribute to the stimulation of cancellous bone formation by ovarian hormones in female rats.
    Gallagher AC; Chambers TJ; Tobias JH
    Am J Physiol; 1996 Mar; 270(3 Pt 1):E407-12. PubMed ID: 8638685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?
    Delmas PD; Vergnaud P; Arlot ME; Pastoureau P; Meunier PJ; Nilssen MH
    Bone; 1995 Jun; 16(6):603-10. PubMed ID: 7669436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel EP4 receptor agonist-bisphosphonate conjugate drug (C1) promotes bone formation and improves vertebral mechanical properties in the ovariectomized rat model of postmenopausal bone loss.
    Liu CC; Hu S; Chen G; Georgiou J; Arns S; Kumar NS; Young RN; Grynpas MD
    J Bone Miner Res; 2015 Apr; 30(4):670-80. PubMed ID: 25284325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacology of disodium (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate.
    Reitsma PH; Bijvoet OL; Frijlink WB; Vismans FJ; van Breukelen FJ
    Adv Exp Med Biol; 1980; 128():219-27. PubMed ID: 7424675
    [No Abstract]   [Full Text] [Related]  

  • 30. A rat osteoporotic spine model for the evaluation of bioresorbable bone cements.
    Wang ML; Massie J; Perry A; Garfin SR; Kim CW
    Spine J; 2007; 7(4):466-74. PubMed ID: 17630145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of the bisphosphonate YM175 on bone mineral density, strength, structure, and turnover in ovariectomized beagles on concomitant dietary calcium restriction.
    Motoie H; Nakamura T; O'uchi N; Nishikawa H; Kanoh H; Abe T; Kawashima H
    J Bone Miner Res; 1995 Jun; 10(6):910-20. PubMed ID: 7572315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-activity relationships of various bisphosphonates.
    Shinoda H; Adamek G; Felix R; Fleisch H; Schenk R; Hagan P
    Calcif Tissue Int; 1983; 35(1):87-99. PubMed ID: 6839194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro.
    Reitsma PH; Teitelbaum SL; Bijvoet OL; Kahn AJ
    J Clin Invest; 1982 Nov; 70(5):927-33. PubMed ID: 7130396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone mass homeostasis and bisphosphonate action.
    Rodan GA
    Bone; 1997 Jan; 20(1):1-4. PubMed ID: 8988341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
    Hornby SB; Evans GP; Hornby SL; Pataki A; Glatt M; Green JR
    Calcif Tissue Int; 2003 Apr; 72(4):519-27. PubMed ID: 12574877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrogen suppresses activation but enhances formation phase of osteogenic response to mechanical stimulation in rat bone.
    Jagger CJ; Chow JW; Chambers TJ
    J Clin Invest; 1996 Nov; 98(10):2351-7. PubMed ID: 8941653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisphosphonate effects in rat unloaded hindlimb bone loss model: three-dimensional microcomputed tomographic, histomorphometric, and densitometric analyses.
    Barou O; Lafage-Proust MH; Martel C; Thomas T; Tirode F; Laroche N; Barbier A; Alexandre C; Vico L
    J Pharmacol Exp Ther; 1999 Oct; 291(1):321-8. PubMed ID: 10490920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of growth hormone and low dose estrogen on bone growth and turnover in long bones of hypophysectomized rats.
    Kidder LS; Schmidt IU; Evans GL; Turner RT
    Calcif Tissue Int; 1997 Oct; 61(4):327-35. PubMed ID: 9312204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
    Azuma Y; Sato H; Oue Y; Okabe K; Ohta T; Tsuchimoto M; Kiyoki M
    Bone; 1995 Feb; 16(2):235-45. PubMed ID: 7756053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo.
    van der Pluijm G; Binderup L; Bramm E; van der Wee-Pals L; De Groot H; Binderup E; Löwik C; Papapoulos S
    J Bone Miner Res; 1992 Aug; 7(8):981-6. PubMed ID: 1442212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.